All lobbying filings

E3 STRATEGIC CONSULTING GROUP

E3 STRATEGIC CONSULTING GROUP filed a Q4 report for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION on January 16, 2026, reporting $50,000 in lobbying income.

Lobbying for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION · Association

All filings by E3 STRATEGIC CONSULTING GROUP · Everything PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 16, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Virginia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, supply chain issues, pharmacy benefit managers transparency issues, Intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act;" S. 3345 - "PBM Price Transparency and Accountability Act."

Bills named in this filing 5

S. 1040
Drug Competition Enhancement Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 4317
PBM Reform Act of 2025
H.R. 5256
340B ACCESS Act
S. 3345
PBM Price Transparency and Accountability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.